Home

Paul B Manning

CIK 1494695 · last filed 2026-07-01

Paul B Manning is a corporate insider who has filed 77 SEC Form 4 insider transactions across 7 companies since 2016. The most recent filing, for CADL, was dated Jul 1, 2026. Across all open-market trades the lifetime net is +$75.2M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $141.8M across reported positions. 6 SEC filings were submitted jointly with PBM Capital Investments, LLC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$141.78M

Companies

7

Total Filings

77

Lifetime Open-Market Net

$75.20M

Filer Profile

Reported Address
200 GARRETT STREET SUITE S
CHARLOTTESVILLE, VA 22902
Related Filers
PBM Capital Investments, LLC — 6 joint filings, latest 2017-11-13
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CADL Director 2,984,752 $11.16 $33.32M $23.91M 13 2026-07-01
LQDA Director 911,139 $68.53 $62.44M -$24.24M 16 2026-06-18
VRCA Director 7,306,561 $4.49 $32.81M $48.04M 17 2025-11-25
TSHA Director 1,355,333 $4.74 $6.42M $25.15M 13 2025-06-03
ABOS 10%+ Owner 3,040,193 $2.23 $6.79M $5.00M 1 2021-07-08
Dova Pharmaceuticals Inc. (DOVA) Delisted Director 0 — — $7.34M 8 2019-11-12
AveXis, Inc. (AVXS) Delisted Director 0 — — -$10.00M 6 2018-05-15

Recent Filings

77 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-07-01 CADL Grant (A) — $0 EDGAR
2026-06-24 CADL Grant (A) — $0 EDGAR
2026-06-18 LQDA Grant (A) +5,882 $0 EDGAR
2026-06-08 LQDA Sell (S) −200,000 -$12.78M EDGAR
2026-06-04 LQDA Notice (144) −200,000 -$11.14M EDGAR
2026-04-02 CADL Grant (A) — $0 EDGAR
2026-02-26 CADL Buy (P) +550,458 $3.00M EDGAR
2026-02-12 LQDA Other (J) — $0 EDGAR
2025-11-25 VRCA Buy (P) +4,126,142 $17.51M EDGAR
2025-09-02 LQDA Sell (S) −670,837 -$18.96M EDGAR
Showing 1–10 of 77
Page 1 of 8
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.